Arvinas, Inc. (ARVN) has been beaten down lately with too much selling pressure. While the stock has lost 54% over the past four weeks, there is light at the end of the tunnel as it is now in ...
and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial NEW ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback